EASi-KIDNEY is an international, multi-centre, randomised double-blind placebo-controlled trial which will assess whether a new drug, currently called BI 690517, reduces the risk of kidney disease progression, hospitalisation for heart failure or death from cardiovascular disease in people with chronic kidney disease when it is added to standard care including empagliflozin.
Read more at [ Ссылка ]

свернуть